Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electroacupuncture Combined With NGF for Ischemic Stroke Recovery
NCT05231694Phase 4Recruiting
- Sponsor
- Third Affiliated Hospital of Zhejiang Chinese Medical University
- Start
- Apr 2022
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mouse nerve growth factor in ischemic stroke (4 arms), sponsored by Third Affiliated Hospital of Zhejiang Chinese Medical University. Primary endpoint: basic cure rate at 4 weeks. Started Apr 2022; status: recruiting.
02
Drugs
mouse nerve growth factor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05231694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231694.